The present disclosure provides immunogenic compositions or vaccines against African Swine Fever Virus (ASFV), methods of making and using such immunogenic compositions or vaccines, and methods of administering such immunogenic compositions or vaccines. In some forms, a plurality of ASFV antigens are combined together into a live-vectored multivalent immunogenic composition. In some forms, the live-vectored multivalent immunogenic composition is a multicistronic expression cassette.

Provided a recombinant classical swine fever virus E2 protein comprising at least one mutation at the epitope specifically recognized by the 6B8 monoclonal antibody. Further, the present invention provides an immunogenic composition comprising the recombinant E2 protein of the present invention and the use of the immunogenic composition for preventing and/or treating diseases associated with CSFV in animal. Moreover, the present invention provides a method and a kit for differentiating animals infected with CSFV from animals vaccinated with the immunogenic composition of the present invention.

The present invention describes immunogenic compositions containing immunogenic polypeptides of African Swine Fever (ASF) virus, including immunogenic compositions containing antigens other than ASF viral antigens, including antigens that may be used in immunization against pathogens that cause diarrheal diseases. Methods of eliciting an immune response with the immunogenic compositions as disclosed and methods of treating an ASF infection are also described.

Provided herein are details on the construction of a recombinant African Swine Fever Virus (ASFV) live attenuated vaccine for prevention of ASF caused by various strains of ASFV, such as the highly virulent Georgia 2007 isolate (“ASFV-G”). An exemplary vaccine comprises a deletion of multiple genes allowing for industrial-scale growth in stable cell lines.

The present invention provides a subunit vaccine composition for African swine fever, and a preparation therefor and use thereof, which fall within the technical field of animal vaccines and veterinary biological products. The vaccine comprises an exterior envelope protein CD2V derived from African swine fever virus and an exterior envelope capsid protein p72 derived from African swine fever virus and a pharmaceutically acceptable adjuvant. The method for preparing the vaccine comprises: 1) preparing the exterior envelope protein CD2V derived from African swine fever virus and the exterior envelope capsid protein p72 derived from African swine fever virus; 2) mixing the exterior envelope protein CD2V derived from African swine fever virus with the exterior envelope capsid protein p72 derived from African swine fever virus prepared in step 1), so as to prepare an antigen solution; and 3) emulsifying the antigen solution and ISA 201 VG at a volume ratio of 46:54.

The present invention provides an attenuated African Swine Fever (ASF) virus which lacks a functional version of the following genes: multigene-family 360 genes 9L, 10L, 11L, 12L, 13L and 14L; and multigene-family 505 genes 1R, 2R, 3R and 4R. The invention further provides an attenuated African Swine Fever (ASF) virus which Lacks a functional version of the DP148R gene. The present invention also provides a vaccine comprising such an attenuated virus and its use to prevent ASF. Further, the invention relates to intranasal administration of an attenuated ASF virus.

An aspect of the present invention is related to nucleic acid constructs capable of expressing at least one African swine fever virus (ASFV) antigen that elicits an immune response in a mammal against ASFV virus, and methods of use thereof.

Provided herein are details on the construction of a recombinant African Swine Fever Virus (ASFV) live attenuated vaccine for prevention of ASF caused by various strains of ASFV, such as the highly virulent Georgia 2007 isolate (“ASFV-G”). An exemplary vaccine comprises a deletion of multiple genes allowing for industrial-scale growth in stable cell lines.

Provided herein are details on the construction of a recombinant African Swine Fever Virus (ASFV) live attenuated vaccine for prevention of ASF caused by various strains of ASFV, such as the highly virulent Georgia 2007 isolate (“ASFV-G”). An exemplary vaccine comprises the ASFV-GΔI1771 modified virus, a recombinant ASFV-G modified by deleting a portion of the I177L ORF rendering the I177L gene nonfunctional.

Provided herein are details on the construction of a recombinant African Swine Fever Virus (ASFV) live attenuated vaccine for prevention of ASF caused by various strains of ASFV, such as the highly virulent Georgia 2007 isolate (“ASFV-G”). An exemplary vaccine comprises the ASFV-GΔA137R modified virus, a recombinant ASFV-G modified by deleting a portion of the A137R ORF rendering the A137R gene nonfunctional.